Change in the total number of shares and votes in Recipharm AB (publ) ("Recipharm")

In April 2014, the number of shares in Recipharm has increased by 10,443,038
shares of series B,  corresponding to 10,443,038 votes, as a result of two new
issues made in connection with Recipharm’s IPO and subsequent listing on NASDAQ
OMX Stockholm.
Furthermore, during the same period, 1,374,407 shares of series C have been
issued in connection with the conversion of outstanding convertible bonds in
Recipharm. These shares of series C have been converted into shares of series B.
In total, 97.8 percent of the convertible bonds have been converted into
shares.

As of 30 April 2014, the share capital in Recipharm amounts to SEK
18,594,437.50, divided into 12,685,716 shares of series A and 24,503,159 shares
of series B. The total number of votes in Recipharm as of 30 April 2014 amounts
to 151,360,319.

This information is published in accordance with Chapter 4, Section 9 of the
Financial Instruments Trading Act (1991:980).

For further information please visit www.recipharm.com or contact:
Thomas Eldered, CEO, thomas.eldered@recipharm.com, telephone: +46 8 602 52 10
Björn Westberg, CFO, bjorn.westberg@recipharm.com, telephone: +46 8 602 46 20

This information is published in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the regulations of
NASDAQ OMX Stockholm. This information was submitted for publication on 30
April, 2014, at 12.00 pm CET.
Recipharm AB (publ)
Corporate identity number 556498-4825
Street address Lagervägen 7, Jordbro Telephone +46 8 602 52 00
Postal address Lagervägen 7, SE-136 50 Jordbro Fax +46 8 81 87 03
www.recipharm.com
About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry based in Sweden employing some
1,500 employees. Recipharm offers manufacturing services of pharmaceuticals in
various dosage forms, production of clinical trial material and pharmaceutical
product development. Recipharm currently manufactures more than 200 different
products to both Big Pharma and smaller research- and development companies.
Recipharm’s turnover is approximately SEK 2.1 billion and the Company operates
development and manufacturing facilities in Sweden, France, the UK, Germany and
Spain and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is
listed on Nasdaq OMX Stockholm.